Heng Du
- Oncology top 10%
- Vascular Tumors and Angiosarcomas 8
- Inflammatory Biomarkers in Disease Prognosis 5
-
- Lung Cancer Diagnosis and Treatment 11
- Renal cell carcinoma treatment 7
- Lung Cancer Treatments and Mutations 6
- Physiology top 10%
- Tuberous Sclerosis Complex Research 15
- Histiocytic Disorders and Treatments 4
-
- Spine and Intervertebral Disc Pathology 5
Heng Du
67 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 94
- Oncology 399
- Pulmonary and Respiratory Medicine 373
- Cancer Research 151
- Physiology 216
- Pathology and Forensic Medicine 99
Countries citing papers authored by Heng Du
This map shows the geographic impact of Heng Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heng Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heng Du more than expected).
Fields of papers citing papers by Heng Du
This network shows the impact of papers produced by Heng Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heng Du. The network helps show where Heng Du may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Heng Du, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 1 | |
| 5 | 2024 | 6 | |
| 6 | 2024 | 16 | |
| 7 | 2024 | 0 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 55 | |
| 10 | 2023 | 26 | |
| 11 | 2021 | 6 | |
| 12 | 2021 | 17 | |
| 13 | Evaluating the Performance of p16INK4a Immunocytochemistry in Cervical Cancer Screening | 2020 | 1 |
| 14 | Metabolic Syndrome Predicts Poor Outcome in Acute Ischemic Stroke Patients After Endovascular Thrombectomy | 2020 | 1 |
| 15 | 2020 | 27 | |
| 16 | 2019 | 17 | |
| 17 | 2019 | 23 | |
| 18 | 2017 | 8 | |
| 19 | 2017 | 14 | |
| 20 | 2016 | 3 |
About Heng Du
Heng Du is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Physiology, Cancer Research and Internal Medicine, having authored 74 papers that have together received 1.1k indexed citations. Recurring topics across this work include Tuberous Sclerosis Complex Research (15 papers), Lung Cancer Diagnosis and Treatment (11 papers), Vascular Tumors and Angiosarcomas (8 papers), Renal cell carcinoma treatment (7 papers), Lung Cancer Treatments and Mutations (6 papers), Spine and Intervertebral Disc Pathology (5 papers), Inflammatory Biomarkers in Disease Prognosis (5 papers) and Histiocytic Disorders and Treatments (4 papers). The work is most often cited by research in Oncology (399 citations), Pulmonary and Respiratory Medicine (373 citations), Cancer Research (151 citations), Physiology (216 citations) and Pathology and Forensic Medicine (99 citations). Heng Du has collaborated with scholars based in China, United States and Switzerland. Frequent co-authors include Guowei Che, Shuangjiang Li, Jun Fan, David J. Kwiatkowski, Yubin Zhou, Jian Huang, Dali Chen, Lunxu Liu, Elizabeth P. Henske and Cheng Shen. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Surgery, Arthritis Research & Therapy, Molecular Cancer Therapeutics and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.